Get an early preview of the new iBridge Network

Access new technology search features and an extended innovation database with new transformative technologies
fed into the platform by our member Academic Institutions, Research Labs, SMEs, Startups


Protection Of The Esophagus From Irradiation Damage By MnSOD-Plasmid-Liposome Gene Therapy

University of Pittsburgh
posted on 07/02/2007

The present invention provides a method of protecting normal cells of the oral cavity, oropharynx, esophagus, stomach, small intestine and colon against the damaging effects of an anticancer agent or ionizing radiation by providing genes encoding antioxidant proteins protective to normal somatic cells, specifically MnSOD. Additional embodiments provide a method of delivering the protective protein via ingestion or inhalation.

Suggested Uses

  • Cytoprotective agent for cancer patients


  • Allows proper dose escalation of radiation therapy and chemotherapy
  • Can be localized to specific organs
  • Does not cause increase in blood pressure, kidney failure, nausea, vomiting, and transient hypotension attributable to other cytoprotective agents
  • First targeted radioprotective agent that demonstrates efficacy in lung and esophagus cancer
  • Competing technologies have questionable efficacy in preventing damage to normal tissues

Innovation Details

Detailed Description

A method of protecting a subject against an agent that elicits production of toxic free radicals, superoxide anions, or heavy metal cations in the subject is disclosed which entails in vivo administration to the subject of a polynucleotide encoding a protein that is transiently expressed in said subject. The transiently expressed protein is capable of neutralizing or eliminating the toxic free radicals, superoxide anions or heavy metal cations that are elicited by the agent. The method is particularly useful in preventing the development of esophagitis during treatment of lung cancer patients with ionizing radiation and/or chemotherapeutic drugs.

File Number: 237 

Other Information:

Stage of Development

Currently in Phase I/II clinical studies at the University of Pittsburgh

IP Protection

Patent Number(s): 6887856

License Online

This innovation currently is not available for online licensing. Please contact Alexander Ducruet at University of Pittsburgh for more information.

Request more info via email request more info

Case Manager:

Alexander Ducruet Alexander Ducruet

Innovations (99)

Download Technology Brief (PDF)

Followed By

Follow this innovation

No one is following this innovation.

Related Tags

Find more innovations

February 11, 2009

13,716 members 17,882 innovations 176 organizations


Alan Thomas, Director, UChicagoTech

"The iBridge Network has opened up new avenues for innovations at UChicagoTech. Relationships between researchers from other universities or industry can be built and strengthened, while investors can find new technologies to advance. "  read more...